BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Surve DH, Jindal AB. Recent advances in long-acting nanoformulations for delivery of antiretroviral drugs. J Control Release 2020;324:379-404. [PMID: 32461114 DOI: 10.1016/j.jconrel.2020.05.022] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 12.0] [Reference Citation Analysis]
Number Citing Articles
1 Sarode IM, Jindal AB. Current status of dolutegravir delivery systems for the treatment of HIV-1 infection. Journal of Drug Delivery Science and Technology 2022;76:103802. [DOI: 10.1016/j.jddst.2022.103802] [Reference Citation Analysis]
2 Park JS, Kim MS, Joung MY, Park HJ, Ho MJ, Choi JH, Seo JH, Song WH, Choi YW, Lee S, Choi YS, Kang MJ. Design of Montelukast Nanocrystalline Suspension for Parenteral Prolonged Delivery. Int J Nanomedicine 2022;17:3673-90. [PMID: 36046838 DOI: 10.2147/IJN.S375888] [Reference Citation Analysis]
3 Xu Z, Liu T, Jiang Y, Chen Z, Shi X, Xu Y, Yu N, Hua X, Liang XJ, Yuan X, Guo S. Microcrystals of Ketal-Linked Paliperidone Prodrugs for Long-Acting Antipsychotics. Mol Pharm 2022. [PMID: 36047719 DOI: 10.1021/acs.molpharmaceut.2c00348] [Reference Citation Analysis]
4 Thoueille P, Alves Saldanha S, Schaller F, Munting A, Cavassini M, Braun D, Günthard HF, Kusejko K, Surial B, Furrer H, Rauch A, Ustero P, Calmy A, Stoeckle M, Battegay M, Marzolini C, Andre P, Guidi M, Buclin T, Decosterd LA; on behalf of the Swiss HIV Cohort Study. Real-Life Therapeutic Concentration Monitoring of Long-Acting Cabotegravir and Rilpivirine: Preliminary Results of an Ongoing Prospective Observational Study in Switzerland. Pharmaceutics 2022;14:1588. [DOI: 10.3390/pharmaceutics14081588] [Reference Citation Analysis]
5 Lu L, Xu Q, Wang J, Wu S, Luo Z, Lu W. Drug Nanocrystals for Active Tumor-Targeted Drug Delivery. Pharmaceutics 2022;14:797. [DOI: 10.3390/pharmaceutics14040797] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
6 Mcguckin MB, Wang J, Ghanma R, Qin N, Palma SD, Donnelly RF, Paredes AJ. Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes. Journal of Controlled Release 2022. [DOI: 10.1016/j.jconrel.2022.03.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 14] [Article Influence: 10.0] [Reference Citation Analysis]
7 Useinova* АN, Mar’yanenko SP, Egorova EA, Ivancova NL. Nanosystems for the delivery of antiretroviral drugs: opportunities, problems, and prospects. VIČ-infekc immunosupr 2022;13:64-76. [DOI: 10.22328/2077-9828-2021-13-4-64-76] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Jampílek J, Kráľová K. Nanotechnology: New frontiers in anti-HIV therapy. Nanotechnological Applications in Virology 2022. [DOI: 10.1016/b978-0-323-99596-2.00011-x] [Reference Citation Analysis]
9 Surve DH, Jindal AB. Development of cationic Isometamidium chloride loaded long-acting lipid nanoformulation: optimization, cellular uptake, pharmacokinetics, biodistribution, and immunohistochemical evaluation. Eur J Pharm Sci 2021;167:106024. [PMID: 34592462 DOI: 10.1016/j.ejps.2021.106024] [Reference Citation Analysis]
10 Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother 2021:dkab324. [PMID: 34499731 DOI: 10.1093/jac/dkab324] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
11 Terrade G, Huot N, Petitdemange C, Lazzerini M, Orta Resendiz A, Jacquelin B, Müller-Trutwin M. Interests of the Non-Human Primate Models for HIV Cure Research. Vaccines (Basel) 2021;9:958. [PMID: 34579195 DOI: 10.3390/vaccines9090958] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Sinha B, Staufenbiel S, Müller RH, Möschwitzer JP. Sub-50 nm ultra-small organic drug nanosuspension prepared by cavi-precipitation and its brain targeting potential. Int J Pharm 2021;607:120983. [PMID: 34371150 DOI: 10.1016/j.ijpharm.2021.120983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Shi Y, Lu A, Wang X, Belhadj Z, Wang J, Zhang Q. A review of existing strategies for designing long-acting parenteral formulations: Focus on underlying mechanisms, and future perspectives. Acta Pharm Sin B 2021;11:2396-415. [PMID: 34522592 DOI: 10.1016/j.apsb.2021.05.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 11.0] [Reference Citation Analysis]
14 Khuroo T, Dharani S, Mohamed EM, Immadi S, Wu Z, Khan MA, Lu D, Nehete P, Rahman Z. Ultra-long acting prodrug of dolutegravir and delivery system - Physicochemical, pharmacokinetic and formulation characterizations. Int J Pharm 2021;607:120889. [PMID: 34271151 DOI: 10.1016/j.ijpharm.2021.120889] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
15 Mutalik SP, Mullick P, Pandey A, Kulkarni SS, Mutalik S. Box-Behnken design aided optimization and validation of developed reverse phase HPLC analytical method for simultaneous quantification of dolutegravir sodium and lamivudine co-loaded in nano-liposomes. J Sep Sci 2021;44:2917-31. [PMID: 34076952 DOI: 10.1002/jssc.202100152] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Elbrink K, Van Hees S, Chamanza R, Roelant D, Loomans T, Holm R, Kiekens F. Application of solid lipid nanoparticles as a long-term drug delivery platform for intramuscular and subcutaneous administration: In vitro and in vivo evaluation. Eur J Pharm Biopharm 2021;163:158-70. [PMID: 33848628 DOI: 10.1016/j.ejpb.2021.04.004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 6.0] [Reference Citation Analysis]
17 Arzi RS, Kay A, Raychman Y, Sosnik A. Excipient-Free Pure Drug Nanoparticles Fabricated by Microfluidic Hydrodynamic Focusing. Pharmaceutics 2021;13:529. [PMID: 33920184 DOI: 10.3390/pharmaceutics13040529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
18 Castellino S, Lareau NM, Groseclose MR. The emergence of imaging mass spectrometry in drug discovery and development: Making a difference by driving decision making. J Mass Spectrom 2021;56:e4717. [PMID: 33724654 DOI: 10.1002/jms.4717] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
19 Bahadur S, Pardhi DM, Rautio J, Rosenholm JM, Pathak K. Intranasal Nanoemulsions for Direct Nose-to-Brain Delivery of Actives for CNS Disorders. Pharmaceutics 2020;12:E1230. [PMID: 33352959 DOI: 10.3390/pharmaceutics12121230] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 11.5] [Reference Citation Analysis]
20 Doroudian M, O' Neill A, Mac Loughlin R, Prina-Mello A, Volkov Y, Donnelly SC. Nanotechnology in pulmonary medicine. Curr Opin Pharmacol 2021;56:85-92. [PMID: 33341460 DOI: 10.1016/j.coph.2020.11.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 9.0] [Reference Citation Analysis]
21 Ho DK, LeGuyader C, Srinivasan S, Roy D, Vlaskin V, Chavas TEJ, Lopez CL, Snyder JM, Postma A, Chiefari J, Stayton PS. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery. J Control Release 2021;329:257-69. [PMID: 33217474 DOI: 10.1016/j.jconrel.2020.11.030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
22 Macchione MA, Aristizabal Bedoya D, Figueroa FN, Muñoz-Fernández MÁ, Strumia MC. Nanosystems Applied to HIV Infection: Prevention and Treatments. Int J Mol Sci 2020;21:E8647. [PMID: 33212766 DOI: 10.3390/ijms21228647] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
23 Sang Y, Ding L, Zhuang C, Chen F. Design strategies for long-acting anti-HIV pharmaceuticals. Curr Opin Pharmacol 2020;54:158-65. [PMID: 33176247 DOI: 10.1016/j.coph.2020.10.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
24 Surve DH, Jirwankar YB, Dighe VD, Jindal AB. Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer–Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and In Vivo Biodistribution. Mol Pharmaceutics 2020;17:3990-4003. [DOI: 10.1021/acs.molpharmaceut.0c00773] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]